Amide derivative with RSV (Respiratory Syndrome Virus) inhibitory activity as well as preparation method and application thereof

By developing a novel amide derivative, the problem of complex and easy metabolism of existing RSV inhibitor synthesis has been solved, simplified synthesis and improved biological activity has been achieved, and effective treatment and prevention methods for RSV infection have been provided, with far-reaching significance.

CN119060016AActive Publication Date: 2024-12-03HANGZHOU NORMAL UNIVERSITY

Patent Information

Application Number
CN202410945064.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-14
Filing Date
2024-07-15
Publication Date
2024-12-03
Estimated Expiration
2044-07-15

AI Technical Summary

Technical Problem

The synthesis of existing RSV inhibitors is complex and easily metabolized by metabolic enzymes, resulting in poor drug properties and limited efficacy and high cost of existing therapies, making it difficult to effectively prevent and treat RSV infection.

Method used

A novel amide derivative has been developed with a simplified structure and strong RSV inhibitory activity, which improves the bioactivity and stability of the drug by optimizing the synthesis route and selecting suitable raw materials, and provides its in treatment and prevention Application methods for RSV infection.

Benefits of technology

The simplified synthesis route was achieved, the RSV inhibitory activity was maintained, and new RSV infection response methods were provided, with potential far-reaching significance and safe and effective therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060016A_ABST
    Figure CN119060016A_ABST
Patent Text Reader

Abstract

The invention discloses an amide derivative with RSV (Respiratory Syndrome Virus) inhibitory activity as well as a preparation method and application thereof. The invention provides an amide derivative with RSV (Respiratory Syndrome Virus) inhibitory activity, a pharmaceutical composition and hydrate containing the derivative as shown in a formula (I), and isotope derivatives, chiral isomers, allosteres, different salts, prodrugs, preparations and the like of the compounds. The invention also provides a preparation method of the amide derivative with RSV virus inhibitory activity and application of the compounds in virus resistance. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to an amide derivative having respiratory syncytial virus (RSV) inhibitory activity, and a preparation method and application thereof. Background Art

[0002] Respiratory Syncytial Virus (RSV) is a non-segmented, negative-strand, enveloped RNA virus belonging to the family Paramyxoviridae, genus Pneumovirus, subfamily Mycoplasma pneumoniae. RSV is an important pathogen of human respiratory diseases, the main cause of lower respiratory tract diseases and bronchiolitis in children, and an important cause of morbidity and mortality in the elderly and immunocompromised patients.

[0003] The RSV gene is a single-stranded, non-segmented, negative RNA molecule that contains 10 genes encoding 11 proteins: NS1, NS2, N, P, M, SH, G, F, M2-1, M2-2, and L (the m gene encodes two proteins, M2-1 and M2-2). The genomic RNA is encapsidated in a nucleocapsid composed of the N protein, RNA polymerase (L protein), its cofactor (P protein), and the M2-1 protein. HRSV can be divided into two subtypes, type A and type B, based on the antigenicity of the G protein. Each subtype is divided into different genotypes based on the different nucleotide sequences of the second highly variable region at the C-terminus of the G gene.

[0004] The prevalence of RSV is also related to the subtypes of the virus (A, B). Subtype A has high polymorphism, and subtype B evolves faster than subtype A. Overall, the nucleotide metabolic rates of the two subtypes are consistent. There are also differences in the epidemic patterns of the two subtypes, and most infections are dominated by one subtype (subtype A). RSV is mainly transmitted in the air through droplets and close contact, and is infected through inhalation through the mouth and nose. The incubation period in the body is 3 to 7 days, and the survival time on the surface of objects is 12 to 24 hours. During this period, close contact may also cause infection with the virus.

[0005] Prevention and treatment of RSV remain enormous challenges. Currently, there are two therapies licensed for the treatment of disease caused by severe RSV infection. Ribavirin, the first licensed treatment, is an antiviral nucleoside analog recommended for the treatment of severe RSV infection in 1993. However, clinical trials of this drug were methodologically flawed, and the efficacy of Ribavirin was exaggerated. Subsequent studies found that the benefit of ribavirin was limited or non-existent. The only currently licensed preventive measure, Palivizumab, a humanized monoclonal antibody against RSV, was licensed in 1998 for the prevention of RSV infection. Due to the high cost, limited efficacy, and the need for monthly preventive injections, Palivizumab is only used in high-risk infants.

[0006] The development of RSV inhibitors with novel structures is of great significance. WO2022 / 092141 discloses an amide derivative I-082 with antiviral activity, the structure of which is as follows: I-082 has strong inhibitory activity against the two antigenic subtypes A and B of RSV, but the synthesis of the hexahydrospiro[indole-3,4'-pyran] part in its structure is relatively complicated, and the six-membered heterocyclic ring containing oxygen atoms is easily metabolized by metabolic enzymes, which is not conducive to obtaining good drugability. Based on this, the present invention explores many different alternative groups of the "hexahydrospiro[indole-3,4'-pyran] part". Summary of the invention

[0007] The first objective of the present invention is to provide a novel amide derivative having RSV inhibitory activity in view of the shortcomings of the prior art such as the complex synthesis of the "hexahydrospiro[indole-3,4'-pyran] part" and the ease of being metabolized by metabolic enzymes.

[0008] An amide derivative having anti-RSV virus inhibitory activity, or its optical isomer, racemate, single enantiomer, possible diastereomer, or its pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate, wherein the structure of the derivative is shown in formula (I):

[0009]

[0010] in:

[0011] R is a hydrogen atom, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted carbamoyl group, a hydroxyl group, a halogen group, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group;

[0012] m is any natural number among 0, 1, 2, 3, 4, 5. When m is 0, n is any natural number among 3, 4, 5, 7, 8. When m is 1, 2, 3, 4, 5, n is any natural number among 0, 1, 2, 3, 4, 5.

[0013] L is selected from one of the following structures

[0014] R 1 is carboxyl, cyano, substituted or unsubstituted aromatic heterocyclic group, -C(=O)-NR 1B R 1C or -CH=CHC(=O)-OH;

[0015] R 1B and R 1C are each independently a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aminosulfonyl group, or a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group;

[0016] R 2 is a substituted or unsubstituted alkyl group;

[0017] V is -CR V Or -N=, W=CR W or =N-;

[0018] R V and R W Each is independently a hydrogen atom, a cyano group, a halogen-substituted or unsubstituted alkyl group, or a substituted or unsubstituted carbamoyl group.

[0019] Preferably, R includes but is not limited to the following structures:

[0020]

[0021] Preferably, L is

[0022] Preferably, R 1 It is a carboxyl group.

[0023] Preferably, the chemical structural formula of the amide derivative having anti-RSV virus inhibitory activity is any one of the following formulas 1 to 24:

[0024]

[0025] A method for preparing the above-mentioned amide derivative having anti-RSV virus inhibitory activity, the synthetic route of the method is as follows:

[0026]

[0027] The raw materials A1 and A2 undergo a substitution reaction to obtain an intermediate A3; A3 and intermediate A4 undergo a substitution reaction to obtain A5; A5 undergoes an ester hydrolysis reaction to obtain a carboxylic acid intermediate A6; finally, A6 and A7 undergo an acid-ammonia condensation to obtain a compound represented by formula (I).

[0028] The compound of formula (I) of the present invention can be prepared by the above method, but the conditions of the method, such as reactants, solvents, the amount of the compound used, reaction temperature, reaction time, etc. are not limited to the above explanation. The compound of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, and such combination can be easily performed by a technician in the field to which the present invention belongs.

[0029] The third object of the present invention is to provide the use of the amide derivative with anti-RSV virus inhibitory activity, or its optical isomers, racemates, single enantiomers, possible diastereomers, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates in the preparation of drugs for treating or preventing viruses.

[0030] The compounds of the present invention have been found to be inhibitors of RSV in biological tests. The compounds are therefore useful in treatment. Therefore, the present invention further provides compounds, as defined above, which are structures of formula (I) or pharmaceutically acceptable salts thereof, for use in methods for treating human or animal bodies. The present invention also provides the compounds of the present invention defined above, for use in methods for treating or preventing RSV infection. Further, the present invention provides the use of the compounds of the present invention defined above in the manufacture of medicaments for treating or preventing RSV infection. Objects suffering from or susceptible to RSV infection can therefore be treated by methods including administering the compounds of the present invention defined above to them. The condition of the object can thus be improved or alleviated.

[0031] In one embodiment the invention provides compounds defined above for treating or preventing RSV infection in pediatric patients. Alternatively infection can be an infection in a mature or elderly adult, for example an adult greater than 60 years old, an adult greater than 70 years old, or an adult greater than 80 years old. The invention further provides compounds for treating or preventing RSV infection in elderly patients.

[0032] The fourth object of the present invention is to provide an antiviral drug containing a safe and effective amount of the above-mentioned amide derivative with anti-RSV virus inhibitory activity, or its optical isomers, racemates, single enantiomers, possible diastereomers, or its pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates.

[0033] Preferably, the antiviral drug may further include a pharmacologically acceptable salt and a pharmacologically acceptable excipient or carrier.

[0034] Since the compounds of the present invention have the activity of inhibiting RSV virus, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate various diseases.

[0035] The "safe and effective amount" of the present invention means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, and more preferably, contains 5-1000 mg of the compound of the present invention per dose. Preferably, the "one dose" is one capsule or tablet.

[0036] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers Wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0037] The administration method of the compound or pharmaceutical composition of the present invention is not particularly limited. Representative administration methods include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous) and topical administration.

[0038] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or solubilizers, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic; (c) humectants, such as glycerol; (d) disintegrators, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) solubilizers, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0039] Solid dosage forms, such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microcapsules with one or more of the above-mentioned excipients.

[0040] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.

[0041] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0042] Suspensions, in addition to the active compounds, may contain suspending agents, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances.

[0043] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0044] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0045] The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.

[0046] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage, and for a person weighing 60 kg, the daily dosage is usually 1 to 5000 mg, preferably 5 to 2000 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill of a skilled physician.

[0047] Compared with the prior art, the present invention has the following beneficial effects:

[0048] The present invention synthesizes a novel class of amide derivatives with RSV inhibitory activity. The synthesis method is simple and fast, and the raw materials used can be purchased, eliminating the difficulty of synthesizing complex structures. The synthesized amide derivatives still maintain the original good biological activity, thereby increasing the means of dealing with RSV infection. Compared with simple structural modification, it is groundbreaking. The present invention also provides a preparation method and use of amide derivatives with RSV inhibitory activity, and the activity of these compounds in inhibiting RSV genes. The amide derivative compounds in the present invention are expected to become candidate drugs for RSV infection diseases, which has far-reaching significance. DETAILED DESCRIPTION

[0049] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. The operating methods in the following examples where no specific conditions are indicated are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0050] Example 1: Preparation of Compound 1

[0051]

[0052] Step 1: 1a (2000 mg, 17.5 mmoL, 1.0 equivalent), 1b (1949 mg, 19.2 mmoL, 1.2 equivalent), K2CO3 (7245 mg, 52.5 mmoL, 3.0 equivalent) were added to DMF at room temperature, and the mixed solution was reacted at 50 ° C for 3 h. The reaction was complete after TLC detection, the reaction solution was spin-dried, and then the reactant was quenched by adding 250 mL of water. The resulting solution was extracted with 3×250 mL of EtOAc. The organic layers were combined and concentrated. The residue was applied to a silica gel column (ethyl acetate: petroleum ether = 4:1). The collected eluents were combined and concentrated to obtain an oily substance, and a total of 1c (2500 mg, yield 90%) was obtained as a light yellow oily target compound.

[0053] Step 2: Compound 1c (2500 mg, 13.96 mmoL, 1.0 equivalent), DMAP (170 mg, 1.39 mmoL, 0.1 equivalent), and Et3N (11.4 mL, 83.0 mmoL, 6.0 equivalent) were dissolved in DCM at room temperature. The mixed solution was placed in an ice bath, and TsCl (6368 mg, 33.5 mmoL, 2.4 equivalent) was added dropwise at 0°C. The reaction was carried out for 8 hours at 0°C, and the reaction was complete after TLC detection. After the reaction solution was spin-dried, 150 mL of water was then added to the resulting crude product. The resulting solution was extracted with 3×250 mL of EtOAc. The organic layers were combined and concentrated. The residue was applied to a silica gel column (ethyl acetate: petroleum ether = 4:1). The collected eluates were combined and concentrated to obtain a white solid to obtain 1d (2000 mg, yield 90.0%).

[0054] Step 3: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 1i (426 mg, yield 61%) was obtained.

[0055] Step 4: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 1m (240 mg, yield 38%) was obtained.

[0056] Step 5: NaOH (184 mg, 1.45 mmoL, 10.00 equiv) was added to a solution of 1m (240 mg, 0.46 mmoL, 1.00 equiv) in MeOH (2 mL), THF (1 mL) and H2O (1 mL). The resulting solution was stirred at room temperature for 4 h. The reactant was then quenched by adding 2 mL (1 M HCl). The reaction was complete after TLC detection. 150 mL of water was then added to the resulting crude product. The resulting solution was extracted with 3×250 mL of EtOAc. The organic layers were combined and concentrated to give a white solid product, 1n. The crude product was used directly in the next step without purification.

[0057] Step 6: Add compound 1n (116 mg, 0.27 mmoL, 1.0 equivalent) and Et3N (68 mg, 0.675 mmoL, 2.5 equivalent) to DMF (1.5 mL) at room temperature, add HATU (133 mg, 0.35 mmol, 1.3 equivalent), stir for 20 min, then add 1h (81 mg, 0.324 mmoL, 1.2 equivalent) in batches, stir for 2 h. The reaction was complete after TLC detection, and the reaction solution was spin-dried, and then 150 mL of water was added to the resulting crude product. The resulting solution was extracted with 3×150 mL of EtOAc and the organic layers were combined. The organic layer was washed with 250 mL of brine, dried over anhydrous sodium sulfate and reduced pressure, and the resulting crude product was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1) to obtain a yellow solid compound 1p (152 mg, yield 86.0%) for the next step reaction.

[0058] Step 7: Add compound 1p (152 mg, 0.234 mmoL, 1.0 equivalent) to DCM (1 mL) at room temperature, add CF3COOH (1 mL) and stir for 1 h. The reaction was complete after TLC detection, and then 150 mL of water was added to the crude product. The resulting solution was extracted with 3×150 mL of EtOAc and the organic layers were combined. The organic layer was washed with 250 mL of brine, dried over anhydrous sodium sulfate and reduced pressure. The crude product was recrystallized from petroleum ether and dichloromethane to give white solid compound 1 (66 mg, yield 47%). 1 HNMR (500MHz, CDCl3) δ8.67 (s, 1H), 8.52 (d, J = 5.0Hz, 2H), 7.14 (d, J = 7.8Hz, 1H), 6.82 (dd, J = 8. 4,2.5Hz,1H),6.77(d,J=2.5Hz,1H),6.70(t,J=5.0Hz,1H),6.21(s,1H),4.91(s,2H),4.66–4.6 0(m,1H),4.10(t,J=5.6Hz,2H),4.05(q,J=6.4,6.0Hz,4H),2.93(t,J=6.0Hz,2H),2.64(s,2H), 2.19(d,J=13.2Hz,2H),2.05–1.94(m,6H),1.89(s,2H),1.81(s,1H),1.76(q,J=9.1,7.2Hz,5H).

[0059] Example 2: Preparation of Compound 2

[0060]

[0061] Step 1: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 2i (391 mg, yield 55%) was obtained.

[0062] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 2m (267 mg, yield 37%) was obtained.

[0063] Step 3: Refer to the synthesis steps in step 5 of Example 1 to obtain white solid compound 2n. The product is directly used in the next reaction without purification.

[0064] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a yellow oily compound 2m (87 mg, yield 17%) was obtained.

[0065] Step 5: Referring to the synthesis procedure of Step 7 in Example 1, a white solid compound 2 (25 mg, yield 23%) was obtained. 1 HNMR (500MHz, CDCl3) δ8.67 (s, 1H), 8.45 (d, J = 5.1Hz, 2H), 7.41 (d, J = 2.5Hz, 1H), 7.05 (d, J = 8. 4Hz,1H),6.69(dd,J=8.4,2.5Hz,1H),6.63(s,1H),4.51(tt,J=6.6,3.4Hz,1H),4.12–4.01(m, 4H),3.89(dt,J=12.4,4.6Hz,2H),2.80(s,1H),2.74(t,J=6.6Hz,2H),2.59(s,2H),2.15–2.03 (m,3H),2.03–1.97(m,4H),1.97–1.89(m,3H),1.81(d,J=14.6Hz,2H),1.70(d,J=11.6Hz,6H).

[0066] Example 3: Preparation of Compound 3

[0067]

[0068] Step 1: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 3f (370 mg, yield 52%) was obtained.

[0069] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 3m (280 mg, yield 37%) was obtained.

[0070] Step 3: Refer to the synthesis steps in step 5 of Example 1 to obtain white solid compound 3n. The product was used directly in the next reaction without purification.

[0071] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a yellow oily compound 3p (101 mg, yield 23%) was obtained.

[0072] Step 5: Referring to the synthesis procedure of Step 7 in Example 1, a white solid compound 3 (55 mg, yield 54%) was obtained. 1 HNMR (500MHz, CDCl3) δ8.71(s,1H),8.48(d,J=4.9Hz,2H),7.72(d,J=8.9Hz,1H),6.82(dd,J=9.0,2 .9Hz,1H),6.77(s,1H),6.66(s,1H),6.47(s,1H),4.62(tt,J=6.7,3.4Hz,1H),4.17–4.08(m,4H),3. 95(ddd,J=13.6,7.0,3.9Hz,2H),2.82(t,J=6.6Hz,2H),2.65(s,2H),2.30–2.18(m,2H),2.05(td,J= 10.8,9.4,4.4Hz,6H),1.97(ddt,J=10.5,6.7,3.6Hz,2H),1.92(p,J=3.2Hz,2H),1.86–1.73(m,6H).

[0073] Example 4: Preparation of Compound 4

[0074]

[0075] Step 1: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 4i (360 mg, yield 55%) was obtained.

[0076] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 4m (280 mg, yield 37%) was obtained.

[0077] Step 3: Refer to the synthesis steps in step 5 of Example 1 to obtain white solid compound 4n. The product is directly used in the next reaction without purification.

[0078] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a yellow oily compound 4p (120 mg, yield 27%) was obtained.

[0079] Step 5: Referring to the synthesis procedure of step 7 in Example 1, a white solid compound 4 (50 mg, yield 53%) was obtained. 1HNMR(500MHz, CDCl3)δ8.57(s,1H),8.26(d,J=4.8Hz,2H),7.01(d,J=8.3Hz,1H),6.81–6.61(m,2H), 6.42(t,J=4.8Hz,1H),6.22(s,1H),4.84(s,2H),4.47(dt,J=7.5,3.7Hz,1H),4.08(ddd,J=13.4,7.5 ,3.8Hz,2H),4.01(t,J=5.9Hz,2H),3.64(ddd,J=13.1,8.1,3.5Hz,2H),2.80(t,J=5.9Hz,2H),2.52( s,2H),2.17–2.02(m,2H),1.93(tdd,J=13.3,8.6,3.4Hz,4H),1.84–1.71(m,4H),1.71–1.59(m,6H).

[0080] Example 5: Preparation of Compound 5

[0081]

[0082] Step 1: Referring to the synthesis procedure of step 1 of Example 1, a yellow oil 5i (176 mg, yield 84%) was obtained.

[0083] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 5m (100 mg, yield 83%) was obtained.

[0084] Step 3: Refer to the synthesis steps in step 5 of Example 1 to obtain white solid compound 5n. The product was directly used in the next step without purification.

[0085] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a yellow oily compound 5p (50 mg, yield 43%) was obtained.

[0086] Step 5: Referring to the synthesis procedure of step 7 in Example 1, a white solid compound 5 (20 mg, yield 23%) was obtained. 1H NMR (500MHz, CDCl3) δ8.57(s,1H),8.28(d,J=4.8Hz,2H),7.60(d,J=8.9Hz,1H),6.73(dd,J=9.0,2 .9Hz,1H),6.67(d,J=2.8Hz,1H),6.45(s,1H),5.82(s,1H),4.49(s,1H),4.09(td,J=9.2,7.7,4.7H z,2H),4.01(t,J=6.2Hz,2H),3.75(s,3H),2.76–2.69(m,3H),2.49(s,2H),2.11(d,J=13.2Hz,2H) ,1.95(p,J=6.4Hz,4H),1.89(d,J=13.2Hz,3H),1.80(s,5H),1.73–1.61(m,7H),1.59–1.45(m,8H).

[0087] Example 6: Preparation of Compound 6

[0088]

[0089] Step 1: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 6i (259 mg, yield 61%) was obtained.

[0090] Step 2: Compound 6i (250 mg, 0.63 mmol, 1.0 equivalent) was dissolved in MeOH (3 mL), and dioxane hydrochloride (1 mL) was added and reacted at room temperature for 4 h. The reaction was complete after TLC detection, and the reaction solution was concentrated under reduced pressure to obtain compound 6g. The crude product was used directly in the next step without purification.

[0091] Step 3: Referring to the synthesis procedure in step 1 of Example 1, a white solid compound 6m (170 mg, yield 52%) was obtained.

[0092] Step 4: Refer to the synthesis steps of Step 5 in Example 1 to obtain white solid compound 6n. The crude product was directly used in the next reaction without purification.

[0093] Step 5: Referring to the synthesis procedure of Step 6 in Example 1, a white solid compound 6p (79 mg, yield 34%) was obtained.

[0094] Step 6: Referring to the synthesis procedure of step 7 in Example 1, a white solid compound 6 (50 mg, yield 69%) was obtained. 1H NMR (500MHz, DMSO-d6) δ8.53(s,1H),8.38(s,1H),8.32(d,J=4.7Hz,2H),7.30(dd,J=8.4,4.0Hz,1H),7.07( d,J=2.3Hz,1H),6.93(dt,J=8.3,2.9Hz,1H),6.57(t,J=4.7Hz,1H),4.79(t,J=17.9Hz,4H),4.62(qt,J=7.9, 3.6Hz,1H),4.26-4.10(m,2H),3.57-3.44(m,2H),2.46(p,J=1.9Hz,2H),2.06(dd,J=24.7,12.7Hz,4H),1.9 5(ddt,J=13.3,7.0,3.3Hz,2H),1.81-1.71(m,2H),1.70-1.60(m,4H),1.55(ddd,J=20.4,14.2,10.1Hz,4H).

[0095] Example 7: Preparation of Compound 7

[0096]

[0097] Step 1: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 7i (355 mg, yield 95%) was obtained.

[0098] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 7m (120 mg, yield 23%) was obtained.

[0099] Step 3: Refer to the synthesis steps in step 5 of Example 1 to obtain white solid compound 7n. The product is directly used in the next reaction without purification.

[0100] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a yellow oily compound 7p (90 mg, yield 83%) was obtained.

[0101] Step 5: Referring to the synthesis procedure of Step 7 in Example 1, a white solid compound 7 (78 mg, yield 90%) was obtained. 1H NMR (500MHz, DMSO-d6) δ8.62(s,1H),8.36(d,J=4.7Hz,2H),7.30(s,1H),7.12-6.85(m,2H),6.62(t,J=4.8Hz,1H),4.81(d,J=36.5Hz,6H),4.15 (d,J=57.1Hz,2H),3.60(d,J=57.4Hz,2H),2.62(s,2H),2.19(s,2H),2. 03(d,J=36.9Hz,5H),1.74(s,2H),1.69-1.55(m,6H),1.54-1.42(m,3H).

[0102] Example 8: Preparation of Compound 8

[0103]

[0104] Step 1: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 8i (302 mg, yield 61%) was obtained.

[0105] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 8m (206 mg, yield 47%) was obtained.

[0106] Step 3: Refer to the synthesis steps in step 5 of Example 1 to obtain white solid compound 8n. The product was directly used for the next step without purification.

[0107] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a yellow oily compound 8p (160 mg, yield 60%) was obtained.

[0108] Step 5: Referring to the synthesis procedure of Step 7 in Example 1, a white solid compound 8 (36 mg, yield 49%) was obtained. 1 H NMR (500MHz, DMSO-d6) δ8.50 (s, 2H), 8.33 (d, J = 4.7Hz, 2H), 7.13 (t, J = 7.9Hz, 1H), 6.9 4(d,J=8.3Hz,1H),6.76(d,J=7.6Hz,1H),6.58(t,J=4.7Hz,1H),4.82(s,2H),4.78-4. 68(m,1H),4.20-3.86(m,4H),3.69(s,2H),2.83(t,J=6.1Hz,2H),2.47(p,J=1.9Hz,3H ),1.97(d,J=37.2Hz,6H),1.68(s,4H),1.56(d,J=16.1Hz,4H),1.45(d,J=12.4Hz,2H).

[0109] Example 9: Preparation of Compound 9

[0110]

[0111] Step 1: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 9i (302 mg, yield 61%) was obtained.

[0112] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 9m (206 mg, yield 47%) was obtained.

[0113] Step 3: Refer to the synthesis steps in step 5 of Example 1 to obtain white solid compound 9n. The product was directly used for the next step without purification.

[0114] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a yellow oily compound 9p (287 mg, yield 78%) was obtained.

[0115] Step 5: Referring to the synthesis procedure of Step 7 in Example 1, a white solid compound 9 (180 mg, yield 85%) was obtained. 1 H NMR(500MHz,DMSO-d6)δ8.57(s,1H),8.35(d,J=4.7Hz,3H),7.16(t,J=8.0H z,1H),7.01-6.73(m,2H),6.60(t,J=4.9Hz,1H),4.89(s,2H),4.69(s,1H), 4.02(s,4H),3.81-3.59(m,2H),2.78(s,2H),2.57(s,2H),2.08(t,J=17.3H z,4H),1.93(t,J=10.3Hz,3H),1.73(s,2H),1.62(s,6H),1.53-1.35(m,3H).

[0116] Example 10: Preparation of Compound 10

[0117]

[0118] Step 1: Referring to the synthesis procedure of step 1 of Example 1, a yellow oil 10i (832 mg, yield 72%) was obtained.

[0119] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 10m (709 mg, yield 51%) was obtained.

[0120] Step 3: Referring to the synthesis step in step 5 of Example 1, a white solid compound 10n was obtained. The product was directly used for the next step without purification.

[0121] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a yellow oily compound 10p (287 mg, yield 78%) was obtained.

[0122] Step 5: Referring to the synthesis procedure of step 7 in Example 1, a white solid compound 10 (168 mg, yield 62%) was obtained. 1 H NMR (500MHz, DMSO-d6) δ12.25(s,1H),8.52(s,1H),8.41(s,1H),8.31(d,J=4.7Hz,2H),7.11(t,J=7.9Hz,1H),6.9 8(dd,J=8.4,1.3Hz,1H),6.82(dd,J=7.6,1.1Hz,1H),6.57(t,J=4.7Hz,1H),4.55(dt,J=7.6,3.9Hz,1H),3.79(d,J =15.2Hz,4H),3.51(ddd,J=12.6,8.3,3.6Hz,2H),2.69(t,J=6.6Hz,2H),2.50(p,J=1.9Hz,2H),2.06(t,J=10.2Hz ,4H),1.93(p,J=6.8Hz,2H),1.83-1.72(m,4H),1.71-1.60(m,4H),1.52(d,J=12.7Hz,2H),1.35(d,J=14.5Hz,2H).

[0123] Example 11: Preparation of Compound 11

[0124]

[0125] Step 1: Referring to the synthesis procedure of step 1 in Example 1, a yellow oil 11b (530 mg, yield 63%) was obtained.

[0126] Step 2: Referring to the synthesis procedure of Step 2 in Example 1, a yellow solid compound 11c (440 mg, yield 87%) was obtained.

[0127] Step 3: Referring to the synthesis step in step 1 of Example 1, a yellow oily compound 11i (279 mg, yield 65%) was obtained.

[0128] Step 4: Refer to the synthesis steps of Step 5 in Example 1 to obtain white solid compound 11m. The crude product was directly used in the next reaction without purification.

[0129] Step 5: Referring to the synthesis procedure of Step 6 in Example 1, a white solid compound 11p (196 mg, yield 60%) was obtained.

[0130] Step 6: Referring to the synthesis procedure of Step 6 in Example 1, a white solid compound 11 (20 mg, yield 32%) was obtained. 1 H NMR(500MHz,DMSO-d6)δ8.54(s,2H),8.37(d,J=4.8Hz,2H),7.14(d,J=8.4Hz,1H),6.87-6.79 (m,1H),6.74(dd,J=8.3,2.7Hz,1H),6.71(t,J=4.8Hz,1H),5.20-5.09(m,1H),4.90(s,2H),4. 62-4.41(m,2H),4.02(d,J=7.5Hz,2H),3.96(dd,J=10.1,3.9Hz,2H),2.83(t,J=5.9Hz,2H),2 .50(p,J=1.9Hz,3H),2.07(s,4H),1.75(s,2H),1.64(d,J=8.9Hz,4H),1.52(d,J=12.6Hz,2H).

[0131] Example 12: Preparation of Compound 12

[0132]

[0133] Step 1: Referring to the synthesis procedure of step 2 in Example 1, a yellow solid compound 12b (834 mg, yield 97%) was obtained.

[0134] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oily compound 12c (463 mg, yield 82%) was obtained.

[0135] Step 3: Refer to the synthesis steps in step 2 of Example 6 to obtain white solid compound 12d. The reaction was used directly in the next step without purification.

[0136] Step 4: Referring to the synthesis procedure of step 1 in Example 1, a white solid compound 12e (279 mg, yield 65%) was obtained.

[0137] Step 5: Referring to the synthesis steps of Step 5 in Example 1, a white solid compound 12f was obtained. The crude product was directly used in the next step without purification.

[0138] Step 6: Referring to the synthesis procedure of Step 6 in Example 1, 12 g (276 mg, yield 95%) of a white solid compound was obtained.

[0139] Step 7: Referring to the synthesis procedure of Step 7 in Example 1, 12 g (131 mg, yield 51%) of a white solid compound was obtained. 1H NMR (500MHz, DMSO-d6) δ8.54(s,2H),8.33(d,J=4.8Hz,2H),7.09(d,J=8.4Hz,1H),6.84-6.76(m ,1H),6.70(dd,J=8.3,2.6Hz,1H),6.65(t,J=4.8Hz,1H),4.87(s,2H),4.67(p,J=6.9Hz,1H),4. 11(s,2H),4.02(q,J=8.5,7.8Hz,4H),2.88-2.73(m,4H),2.51(q,J=1.8Hz,1H),2.34-2.20(m,2 H),2.07(t,J=13.8Hz,4H),1.99(s,1H),1.76(s,2H),1.64(d,J=8.2Hz,4H),1.56-1.47(m,2H).

[0140] Example 13: Preparation of Compound 13

[0141]

[0142] Step 1: Referring to the synthesis procedure of step 2 in Example 1, a yellow solid compound 13b (176 mg, yield 84%) was obtained.

[0143] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oily compound 13c (372 mg, yield 72%) was obtained.

[0144] Step 3: Refer to the synthesis steps in step 2 of Example 6 to obtain white solid compound 13d. The reaction was used directly in the next step without purification.

[0145] Step 4: Referring to the synthesis procedure of step 1 in Example 1, a white solid compound 13e (276 mg, yield 95%) was obtained.

[0146] Step 5: Referring to the synthesis procedure of Step 5 in Example 1, a white solid compound 13f was obtained. The crude product was directly used in the next step without purification.

[0147] Step 6: Referring to the synthesis procedure of Step 6 in Example 1, 13 g (120 mg, yield 43%) of a white solid compound was obtained.

[0148] Step 7: Referring to the synthesis procedure of Step 7 in Example 1, a white solid compound 13 (47 mg, yield 55%) was obtained. 1H NMR(500MHz,DMSO-d6)δ8.56(s,2H),8.32(d,J=4.7Hz,2H),7.07(d,J=8.5Hz,1H),6.76(s,1H),6.7 1-6.64(m,1H),6.56(t,J=4.7Hz,1H),4.80(d,J=50.0Hz,3H),4.06-3.86(m,2H),3.74(t,J=5.5Hz, 2H),3.66(t,J=5.6Hz,2H),2.78(s,2H),2.50(p,J=1.8Hz,3H),2.45(d,J=9.5Hz,2H),2.06(s,4H), 1.87-1.77(m,2H),1.76-1.66(m,2H),1.66-1.58(m,4H),1.58-1.52(m,3H),1.48(t,J=7.7Hz,2H).

[0149] Example 14: Preparation of Compound 14

[0150]

[0151] Step 1: Add 4i (200 mg, 0.544 mmol), KOH (60 mg, 1.08 mmol), dibenzo-18-crown (9.8 mg, 0.0272 mmol), PhCH3 (5 mL) to compound 1a (124 mg, 1.08 mmol), and heat to 130 ° C and stir for 4 h. After the reaction is completed by TLC detection, water is added to quench the reaction. After the reaction is cooled to room temperature, DCM (10 mL×3) is reacted and washed with NaCl aqueous solution (10 mL). The organic phases are combined and dried over anhydrous Na2SO4. The desiccant is filtered to remove the desiccant, and the filtrate is concentrated and the crude product is purified by silica gel column chromatography (EtOAc / Petroleum ether system elution) to obtain yellow solid compound 14i (94 mg, yield 20%).

[0152] Step 2: Referring to the synthesis procedure of Step 5 in Example 1, a white solid compound 14m was obtained. The crude product was directly used in the next step without purification.

[0153] Step 3: Referring to the synthesis procedure of Step 6 in Example 1, a white solid compound 14p (78 mg, yield 63%) was obtained.

[0154] Step 4: Referring to the synthesis procedure of Step 7 in Example 1, a white solid compound 14 (25 mg, yield 39%) was obtained. 1H NMR (500MHz, DMSO-d6) δ8.63(d,J=4.8Hz,2H),8.55(s,2H),7.38-7.21(m,2H),7.20-7.12(m,1H),7.02(dd,J=8.2,2.5Hz,1H),4.93(s,2H),4.05( d,J=7.6Hz,2H),2.92(t,J=6.0Hz,2H),2.50(p,J=1.8Hz,2H),2.08(d,J= 14.0Hz, 4H), 1.76 (s, 2H), 1.63 (d, J = 17.3Hz, 4H), 1.52 (d, J = 12.6Hz, 2H).

[0155] Example 15: Preparation of Compound 15

[0156]

[0157] Step 1: Referring to the synthesis procedure of step 2 in Example 1, a yellow solid compound 15b (600 mg, yield 85%) was obtained.

[0158] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oily compound 15i (236 mg, yield 44%) was obtained.

[0159] Step 3: Referring to the synthesis procedure of Step 5 in Example 1, a white solid compound 15m was obtained. The crude product was directly used in the next step without purification.

[0160] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a white solid compound 15p (236 mg, yield 71%) was obtained.

[0161] Step 5: Referring to the synthesis procedure of Step 7 in Example 1, a white solid compound 15 (68 mg, yield 45%) was obtained. 1H NMR (500MHz, DMSO-d6) δ8.54(s,1H),8.39(s,1H),7.10(d,J=8.4Hz,1H),6.95(s,1H),6.82(dd,J=8.4,2.6Hz,1H),4. 88(s,2H),4.59(tt,J=8.0,3.7Hz,1H),4.17-3.93(m,2H),3.93-3.77(m,1H),3.67(dd,J=9.3,5.6Hz,1H),3.32(ddd, J=13.1,8.9,3.4Hz,2H),3.21(ddd,J=12.8,8.9,3.6Hz,1H),2.82(t,J=5.8Hz,2H),2.50(p,J=1.9Hz,2H),2.08(t,J= 14.0Hz,4H),2.01(s,3H),1.99-1.91(m,1H),1.88(dq,J=15.0,6.1,5.0Hz,1H),1.78(s,2H),1.66(d,J=11.4Hz,4H).

[0162] Example 16: Preparation of Compound 16

[0163]

[0164] Step 1: Referring to the synthesis procedure of step 2 in Example 1, a yellow solid compound 16b (176 mg, yield 84%) was obtained.

[0165] Step 2: Referring to the synthesis procedure of step 1 in Example 1, a yellow oily compound 16i (500 mg, yield 80%) was obtained.

[0166] Step 3: Referring to the synthesis procedure of Step 5 in Example 1, a white solid compound 16m was obtained. The crude product was directly used in the next step without purification.

[0167] Step 4: Referring to the synthesis procedure of Step 6 in Example 1, a white solid compound 16p (150 mg, yield 75%) was obtained.

[0168] Step 5: Referring to the synthesis procedure of Step 7 in Example 1, a white solid compound 16 (38 mg, yield 40%) was obtained. 1H NMR(500MHz,DMSO-d6)δ8.52(d,J=30.8Hz,2H),7.04(d,J=8.4Hz,1H),6.89(s,1H),6.76(dd,J=8.3,2.6Hz,1H),4 .82(s,2H),4.53(tt,J=7.8,3.5Hz,1H),3.95(t,J=5.7Hz,2H),3.79(dt,J=12.8,4.7Hz,1H),3.61(dt,J=13.8,4. 9Hz,1H),3.27(ddd,J=13.2,8.8,3.4Hz,1H),3.16(ddt,J=14.0,8.6,4.3Hz,1H),2.76(t,J=5.9Hz,2H),2.46(p,J =1.9Hz,2H),1.99(d,J=25.5Hz,7H),1.93-1.79(m,2H),1.74-1.64(m,2H),1.62-1.50(m,5H),1.50-1.38(m,3H).

[0169] Example 17: Test of RSV Inhibitory Activity of Compounds

[0170] 1. Experimental Materials and Instruments

[0171] 2. Experimental Methods

[0172] HEp-2 cells were seeded into microplates at a certain density and cultured overnight in a 5% CO2, 37°C incubator. On the next day, diluted compounds and RSVAlong viruses were added. Cell controls (cells, no compound treatment or virus infection) and virus controls (cells infected with viruses, no compound treatment) were set up. The final concentration of DMSO in the culture medium was 0.5%. The cells were cultured in a 5% CO2, 37°C incubator for 5 days. The cytotoxicity experiment was carried out under the same conditions as the antiviral experiment, but without virus infection. The cell viability was detected using the cell viability detection kit CTG. The antiviral activity and cytotoxicity of the compound were expressed by the inhibition rate (%) of the virus-induced cytopathic effect of the compound at different concentrations and the viability (%) of HEp-2 cells, respectively. GraphPad Prism was used to perform nonlinear fitting analysis on the inhibition rate and cell viability of the compound to calculate the half effective concentration (EC 50 ) and the half cytotoxic concentration (CC 50 )value.

[0173] 3. Experimental results

[0174]

[0175]

[0176] Note: I-082 is the RSV inhibitor with the best activity shown in patent WO2022092141, and ALS-8112 is a reported highly effective and selective respiratory syncytial virus (RSV) polymerase inhibitor.

[0177] + indicates compound EC 50 >10000nM, CC 50 >10000nM

[0178] ++ indicates compound 10000nM>EC 50 >1000nM, 10000nM>CC 50 >1000nM

[0179] +++ indicates compound 1000nM>EC 50 >50nM, 1000nM>CC 50 >50nM,

[0180] ++++ indicates compound EC 50 <50nM, CC 50 <50nM

[0181] Conclusion: Some compounds of the present invention have significant inhibitory effects on RSV, and their activity is comparable to that of I-082 and superior to that of RSV inhibitors ALS-8112, CC 50 The results show that the compounds of the present invention have certain safety.

[0182] Example 18: RSV pharmacokinetic testing of compound

[0183] 1. Experimental Methods

[0184] 18 ICR (Improved Castle Road) mice, SPF grade, weighing 21.10-24.40g, were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd. They were divided into 2 groups: Group 1 (intravenous injection group, 9 mice) and Group 2 (oral administration group, 9 mice), and fasted for 12 hours before administration. Then, ICR mice were administered I-082, 4 and 6 compounds by intravenous injection (iv) of 1 mg / kg and oral gavage (po) of 3 mg / kg, respectively. The solvent for intravenous injection / oral administration: 5% DMSO + 15% SolutolHS15 + 80% PBS (preheated at 40°C). Then, 0.1 ml blood samples were obtained by taking blood from the tail vein at the following time points. Blood sampling time points for intravenous administration: 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h and 24h after administration; blood sampling time points for oral administration: 15min, 30min, 1h, 2h, 4h, 6h, 8h and 24h after administration. The obtained blood samples were placed in anticoagulant tubes containing labeled EDTA-2K. After gently inverting up and down to fully mix the anticoagulant (EDTA-2K) with the blood, it was immediately placed in wet ice and centrifuged within 1h after blood collection to separate plasma. The centrifugation conditions were set to 4℃, 6800r, and 6min. The plasma separated after centrifugation was placed in a labeled EP tube and stored in an ultra-low temperature refrigerator before analysis. The concentration of the drug in the sample in plasma was determined by LC-MS, and the relevant pharmacokinetic parameters were calculated using WinkNonlin software.

[0185] 2. Experimental results

[0186]

[0187] Note: Cassette PK uses mice, and each rat is gavaged or injected with four to five different compounds at the same time.

[0188] Full PK used ICR mice, and each mouse was gavaged or injected with one compound at the same time. Conclusion: Compounds R-011 and R-022 of the present invention have good pharmacokinetic properties, among which compound R-022 has better absorption and utilization than positive compound I-082, and has certain research value.

Claims

1. An amide derivative having anti-RSV virus inhibitory activity, or its optical isomers, racemates, single enantiomers, possible diastereomers, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates, characterized in that: The structure of the derivative is shown in formula (I): in: R is a hydrogen atom, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted carbamoyl group, a hydroxyl group, a halogen group, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group; m is any natural number among 0, 1, 2, 3, 4, 5. When m is 0, n is any natural number among 3, 4, 5, 7, 8. When m is 1, 2, 3, 4, 5, n is any natural number among 0, 1, 2, 3, 4, 5. L is selected from one of the following structures R 1 is carboxyl, cyano, substituted or unsubstituted aromatic heterocyclic group, -C(=O)-NR 1B R 1C or -CH=CHC(=O)-OH; R 1B and R 1C Each is independently a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aminosulfonyl group, or a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group; R 2 is a substituted or unsubstituted alkyl group; V is -CR V Or -N=, W=CR W or =N-; R V and R W Each is independently a hydrogen atom, a cyano group, a halogen-substituted or unsubstituted alkyl group, or a substituted or unsubstituted carbamoyl group.

2. The amide derivative having anti-RSV virus inhibitory activity according to claim 1, wherein R includes the following structure:

3. The amide derivative having anti-RSV virus inhibitory activity according to claim 2, wherein: L is 4. The amide derivative having anti-RSV virus inhibitory activity according to claim 3, wherein R 1 It is a carboxyl group.

5. The amide derivative having anti-RSV virus inhibitory activity according to claim 4, characterized in that: The chemical structural formula of the amide derivative with anti-RSV virus inhibitory activity is any one of the following formulas 1 to 24:

6. A method for preparing an amide derivative having anti-RSV virus inhibitory activity as claimed in any one of claims 1 to 5, wherein the synthetic route of the method is as follows: The raw materials A1 and A2 undergo a substitution reaction to obtain an intermediate A3; A3 and intermediate A4 undergo a substitution reaction to obtain A5; A5 undergoes an ester hydrolysis reaction to obtain a carboxylic acid intermediate A6; finally, A6 and A7 undergo an acid-ammonia condensation to obtain a compound represented by formula (I).

7. Use of the amide derivative with anti-RSV virus inhibitory activity as described in any one of claims 1 to 5, or its optical isomers, racemates, single enantiomers, possible diastereomers, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates in the preparation of antiviral drugs.

8. An antiviral drug containing a safe and effective amount of an amide derivative with anti-RSV virus inhibitory activity as described in any one of claims 1 to 5, or its optical isomers, racemates, single enantiomers, possible diastereomers, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, or solvates.

9. The antiviral drug according to claim 8, characterized in that It also includes pharmacologically acceptable salts and pharmacologically acceptable excipients or carriers.

Citation Information

Patent Citations

  • Amide derivatives having antiviral activity

    CN116528850A

  • PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND

    WO2016148145A1

Cited By

  • Application of sulfonamide derivative in preparation of medicine for treating respiratory syncytial virus pneumonia

    CN122351262A

  • Use of a sulfonamide derivative for the preparation of a medicament for the treatment of respiratory syncytial virus pneumonia

    CN122351262B

  • Heterocyclic compound against respiratory syncytial virus and use thereof

    WO2026179803A1